Onursal Buğra1, Hasan Sunar2

1Balıkesir University, School of Medicine, Department of Cardiovascular Surgery, Balıkesir, Turkey
2Kartal Kosuyolu High Speciality Training and Research Hospital, Clinic of Cardiovascular Surgery, İstanbul, Turkey

Keywords: Nebivolol; metoprolol; coronary artery bypass surgery; renal injury; NGAL


Introduction: This study aimed to determine whether pre-treatment with nebivolol provides better protection against postoperative renal injury than metoprolol in patients undergoing coronary artery bypass grafting.

Patients and Methods: Sixty diabetic patients were divided into two groups as those receiving either nebivolol (Group I, n= 30) or metoprolol (Group II, n= 30) treatment. The patients in Group I were initiated on nebivolol 5 mg/day and those in Group II were initiated on metoprolol 50 mg/day. Postoperative renal functions were assessed by serial measurements of serum neutrophil gelatinase associated lipocalin (NGAL) and serum creatinine levels. P< 0.05 was considered as the level of statistical significance.

Results: Demographic, preoperative clinical parameters and operative variables were similar between the two groups. The number of patients with two-hour NGAL positivity was not different between the two groups (7 [26.9%] vs. 7 [25.9%] p= 0.93). Only 1 patient from each group had higher creatinine values than the reference limit at 24 hours; whereas, 72-hour creatinine positivity was observed in 7 patients from each group. All patients achieved improvement with renal replacement therapy and hemodialysis requirement did not occur.

Conclusion: Any difference between the use of metoprolol and nebivolol was not found in terms of better protection against early renal impairment in diabetic patients who underwent coronary artery bypass grafting.

Cite this article as: Buğra O, Sunar H. Renal protective effect of nebivolol vs. metoprolol in diabetic patients undergoing coronary artery bypass surgery. Koşuyolu Heart J 2020;23(3):163-8.